Erythrocyte lipids and vitamin E in Type II congenital dyserythropoietic anemia

An 8-year-old girl with Type II congenital dyserythropoietic anemia, characterized by morphologic abnormalities of erythroid precursors, immunologic alterations, hyperbilirubinemia, and chronic anemia, was found to be vitamin E deficient. Nutritional history and vitamin E absorption studies indicate...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of pediatrics 1974-03, Vol.84 (3), p.355-361
Hauptverfasser: O'Regan, Sean, Melhorn, David K., Newman, Arthur J., Graham, Richard C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 361
container_issue 3
container_start_page 355
container_title The Journal of pediatrics
container_volume 84
creator O'Regan, Sean
Melhorn, David K.
Newman, Arthur J.
Graham, Richard C.
description An 8-year-old girl with Type II congenital dyserythropoietic anemia, characterized by morphologic abnormalities of erythroid precursors, immunologic alterations, hyperbilirubinemia, and chronic anemia, was found to be vitamin E deficient. Nutritional history and vitamin E absorption studies indicated that neither dietary lack nor intenstinal malabsorption was the cause of the deficiency. Striking changes in the patient's hematologic status following administration of vitamin E included rise in hemoglobin, decrease in bilirubin and reticulocyte count, and a marked increase in red blood cell survival. Erythrocyte phospholipids, altered while the patient was vitamin E deficient, returned to normal levesl during therapy. However, hematologic improvement was not complete, immunolotic abnormalities persisted, and morphologic aberrations in erythrocyte precursors actually increased during vitamin E therapy. It is therefore concluded that vitamin E deficiency played a secondary role in the production of the child's hematologic disorder and may have been a result of the increased utilization of the vitamin in stabilization of defective cellular membranes.
doi_str_mv 10.1016/S0022-3476(74)80716-X
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_82307161</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S002234767480716X</els_id><sourcerecordid>82307161</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-b9b57955a0e5a3a58ef8da7011b563389eb0d42fbda843b1add2c0a868eeaef53</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRS0EKqXwCZWyQrAIjOM4cVYIVQUqVeqCInVnOfYEjPLCTivl70kfYstmZnHvncchZErhgQJNHt8BoihkcZrcpfG9gJQm4eaMjClkaZgIxs7J-M9ySa68_waALAYYkVEsKM1EMiarueu7L9fovsOgtK01PlC1CXa2U5Wtg3kwlHXfYrBYBLqpP7EelDIwvcdjsm0sdlYPKaysuiYXhSo93pz6hHy8zNezt3C5el3MnpehZgl0YZ7lPM04V4BcMcUFFsKoFCjNecKYyDAHE0dFbpSIWU6VMZEGJRKBqLDgbEJuj3Nb1_xs0Xeysl5jWQ5nNFsvRcT2ROhg5Eejdo33DgvZOlsp10sKcg9SHkDKPSWZxvIAUm6G3PS0YJtXaP5SJ3KD_nTUcfhyZ9FJry3WGo11qDtpGvvPhl9E74QR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>82307161</pqid></control><display><type>article</type><title>Erythrocyte lipids and vitamin E in Type II congenital dyserythropoietic anemia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>O'Regan, Sean ; Melhorn, David K. ; Newman, Arthur J. ; Graham, Richard C.</creator><creatorcontrib>O'Regan, Sean ; Melhorn, David K. ; Newman, Arthur J. ; Graham, Richard C.</creatorcontrib><description>An 8-year-old girl with Type II congenital dyserythropoietic anemia, characterized by morphologic abnormalities of erythroid precursors, immunologic alterations, hyperbilirubinemia, and chronic anemia, was found to be vitamin E deficient. Nutritional history and vitamin E absorption studies indicated that neither dietary lack nor intenstinal malabsorption was the cause of the deficiency. Striking changes in the patient's hematologic status following administration of vitamin E included rise in hemoglobin, decrease in bilirubin and reticulocyte count, and a marked increase in red blood cell survival. Erythrocyte phospholipids, altered while the patient was vitamin E deficient, returned to normal levesl during therapy. However, hematologic improvement was not complete, immunolotic abnormalities persisted, and morphologic aberrations in erythrocyte precursors actually increased during vitamin E therapy. It is therefore concluded that vitamin E deficiency played a secondary role in the production of the child's hematologic disorder and may have been a result of the increased utilization of the vitamin in stabilization of defective cellular membranes.</description><identifier>ISSN: 0022-3476</identifier><identifier>EISSN: 1097-6833</identifier><identifier>DOI: 10.1016/S0022-3476(74)80716-X</identifier><identifier>PMID: 4811986</identifier><language>eng</language><publisher>United States: Mosby, Inc</publisher><subject>Anemia, Hemolytic, Congenital - blood ; Anemia, Hemolytic, Congenital - complications ; Anemia, Hemolytic, Congenital - drug therapy ; Anemia, Hemolytic, Congenital - physiopathology ; Bone Marrow Examination ; Cell Membrane Permeability - drug effects ; Child ; Erythrocytes - analysis ; Erythrocytes, Abnormal ; Erythropoiesis - drug effects ; Female ; Humans ; Hyperbilirubinemia - complications ; Phosphatidylethanolamines - blood ; Phospholipids - blood ; Vitamin E - blood ; Vitamin E - pharmacology ; Vitamin E - therapeutic use ; Vitamin E Deficiency - drug therapy</subject><ispartof>The Journal of pediatrics, 1974-03, Vol.84 (3), p.355-361</ispartof><rights>1974 The C. V. Mosby Company</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-b9b57955a0e5a3a58ef8da7011b563389eb0d42fbda843b1add2c0a868eeaef53</citedby><cites>FETCH-LOGICAL-c360t-b9b57955a0e5a3a58ef8da7011b563389eb0d42fbda843b1add2c0a868eeaef53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S002234767480716X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/4811986$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>O'Regan, Sean</creatorcontrib><creatorcontrib>Melhorn, David K.</creatorcontrib><creatorcontrib>Newman, Arthur J.</creatorcontrib><creatorcontrib>Graham, Richard C.</creatorcontrib><title>Erythrocyte lipids and vitamin E in Type II congenital dyserythropoietic anemia</title><title>The Journal of pediatrics</title><addtitle>J Pediatr</addtitle><description>An 8-year-old girl with Type II congenital dyserythropoietic anemia, characterized by morphologic abnormalities of erythroid precursors, immunologic alterations, hyperbilirubinemia, and chronic anemia, was found to be vitamin E deficient. Nutritional history and vitamin E absorption studies indicated that neither dietary lack nor intenstinal malabsorption was the cause of the deficiency. Striking changes in the patient's hematologic status following administration of vitamin E included rise in hemoglobin, decrease in bilirubin and reticulocyte count, and a marked increase in red blood cell survival. Erythrocyte phospholipids, altered while the patient was vitamin E deficient, returned to normal levesl during therapy. However, hematologic improvement was not complete, immunolotic abnormalities persisted, and morphologic aberrations in erythrocyte precursors actually increased during vitamin E therapy. It is therefore concluded that vitamin E deficiency played a secondary role in the production of the child's hematologic disorder and may have been a result of the increased utilization of the vitamin in stabilization of defective cellular membranes.</description><subject>Anemia, Hemolytic, Congenital - blood</subject><subject>Anemia, Hemolytic, Congenital - complications</subject><subject>Anemia, Hemolytic, Congenital - drug therapy</subject><subject>Anemia, Hemolytic, Congenital - physiopathology</subject><subject>Bone Marrow Examination</subject><subject>Cell Membrane Permeability - drug effects</subject><subject>Child</subject><subject>Erythrocytes - analysis</subject><subject>Erythrocytes, Abnormal</subject><subject>Erythropoiesis - drug effects</subject><subject>Female</subject><subject>Humans</subject><subject>Hyperbilirubinemia - complications</subject><subject>Phosphatidylethanolamines - blood</subject><subject>Phospholipids - blood</subject><subject>Vitamin E - blood</subject><subject>Vitamin E - pharmacology</subject><subject>Vitamin E - therapeutic use</subject><subject>Vitamin E Deficiency - drug therapy</subject><issn>0022-3476</issn><issn>1097-6833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1974</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtOwzAQRS0EKqXwCZWyQrAIjOM4cVYIVQUqVeqCInVnOfYEjPLCTivl70kfYstmZnHvncchZErhgQJNHt8BoihkcZrcpfG9gJQm4eaMjClkaZgIxs7J-M9ySa68_waALAYYkVEsKM1EMiarueu7L9fovsOgtK01PlC1CXa2U5Wtg3kwlHXfYrBYBLqpP7EelDIwvcdjsm0sdlYPKaysuiYXhSo93pz6hHy8zNezt3C5el3MnpehZgl0YZ7lPM04V4BcMcUFFsKoFCjNecKYyDAHE0dFbpSIWU6VMZEGJRKBqLDgbEJuj3Nb1_xs0Xeysl5jWQ5nNFsvRcT2ROhg5Eejdo33DgvZOlsp10sKcg9SHkDKPSWZxvIAUm6G3PS0YJtXaP5SJ3KD_nTUcfhyZ9FJry3WGo11qDtpGvvPhl9E74QR</recordid><startdate>197403</startdate><enddate>197403</enddate><creator>O'Regan, Sean</creator><creator>Melhorn, David K.</creator><creator>Newman, Arthur J.</creator><creator>Graham, Richard C.</creator><general>Mosby, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>197403</creationdate><title>Erythrocyte lipids and vitamin E in Type II congenital dyserythropoietic anemia</title><author>O'Regan, Sean ; Melhorn, David K. ; Newman, Arthur J. ; Graham, Richard C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-b9b57955a0e5a3a58ef8da7011b563389eb0d42fbda843b1add2c0a868eeaef53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1974</creationdate><topic>Anemia, Hemolytic, Congenital - blood</topic><topic>Anemia, Hemolytic, Congenital - complications</topic><topic>Anemia, Hemolytic, Congenital - drug therapy</topic><topic>Anemia, Hemolytic, Congenital - physiopathology</topic><topic>Bone Marrow Examination</topic><topic>Cell Membrane Permeability - drug effects</topic><topic>Child</topic><topic>Erythrocytes - analysis</topic><topic>Erythrocytes, Abnormal</topic><topic>Erythropoiesis - drug effects</topic><topic>Female</topic><topic>Humans</topic><topic>Hyperbilirubinemia - complications</topic><topic>Phosphatidylethanolamines - blood</topic><topic>Phospholipids - blood</topic><topic>Vitamin E - blood</topic><topic>Vitamin E - pharmacology</topic><topic>Vitamin E - therapeutic use</topic><topic>Vitamin E Deficiency - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>O'Regan, Sean</creatorcontrib><creatorcontrib>Melhorn, David K.</creatorcontrib><creatorcontrib>Newman, Arthur J.</creatorcontrib><creatorcontrib>Graham, Richard C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>O'Regan, Sean</au><au>Melhorn, David K.</au><au>Newman, Arthur J.</au><au>Graham, Richard C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Erythrocyte lipids and vitamin E in Type II congenital dyserythropoietic anemia</atitle><jtitle>The Journal of pediatrics</jtitle><addtitle>J Pediatr</addtitle><date>1974-03</date><risdate>1974</risdate><volume>84</volume><issue>3</issue><spage>355</spage><epage>361</epage><pages>355-361</pages><issn>0022-3476</issn><eissn>1097-6833</eissn><abstract>An 8-year-old girl with Type II congenital dyserythropoietic anemia, characterized by morphologic abnormalities of erythroid precursors, immunologic alterations, hyperbilirubinemia, and chronic anemia, was found to be vitamin E deficient. Nutritional history and vitamin E absorption studies indicated that neither dietary lack nor intenstinal malabsorption was the cause of the deficiency. Striking changes in the patient's hematologic status following administration of vitamin E included rise in hemoglobin, decrease in bilirubin and reticulocyte count, and a marked increase in red blood cell survival. Erythrocyte phospholipids, altered while the patient was vitamin E deficient, returned to normal levesl during therapy. However, hematologic improvement was not complete, immunolotic abnormalities persisted, and morphologic aberrations in erythrocyte precursors actually increased during vitamin E therapy. It is therefore concluded that vitamin E deficiency played a secondary role in the production of the child's hematologic disorder and may have been a result of the increased utilization of the vitamin in stabilization of defective cellular membranes.</abstract><cop>United States</cop><pub>Mosby, Inc</pub><pmid>4811986</pmid><doi>10.1016/S0022-3476(74)80716-X</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-3476
ispartof The Journal of pediatrics, 1974-03, Vol.84 (3), p.355-361
issn 0022-3476
1097-6833
language eng
recordid cdi_proquest_miscellaneous_82307161
source MEDLINE; Elsevier ScienceDirect Journals
subjects Anemia, Hemolytic, Congenital - blood
Anemia, Hemolytic, Congenital - complications
Anemia, Hemolytic, Congenital - drug therapy
Anemia, Hemolytic, Congenital - physiopathology
Bone Marrow Examination
Cell Membrane Permeability - drug effects
Child
Erythrocytes - analysis
Erythrocytes, Abnormal
Erythropoiesis - drug effects
Female
Humans
Hyperbilirubinemia - complications
Phosphatidylethanolamines - blood
Phospholipids - blood
Vitamin E - blood
Vitamin E - pharmacology
Vitamin E - therapeutic use
Vitamin E Deficiency - drug therapy
title Erythrocyte lipids and vitamin E in Type II congenital dyserythropoietic anemia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T04%3A08%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Erythrocyte%20lipids%20and%20vitamin%20E%20in%20Type%20II%20congenital%20dyserythropoietic%20anemia&rft.jtitle=The%20Journal%20of%20pediatrics&rft.au=O'Regan,%20Sean&rft.date=1974-03&rft.volume=84&rft.issue=3&rft.spage=355&rft.epage=361&rft.pages=355-361&rft.issn=0022-3476&rft.eissn=1097-6833&rft_id=info:doi/10.1016/S0022-3476(74)80716-X&rft_dat=%3Cproquest_cross%3E82307161%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=82307161&rft_id=info:pmid/4811986&rft_els_id=S002234767480716X&rfr_iscdi=true